
Deutsche Bank flags triple upside for psychedelic drug developer as therapy boom grows
Deutsche Bank analysts anticipate a leading psychedelic-drug developer could triple its stock as psychedelic therapies gain mainstream traction, signaling significant upside for investors in this biotech niche.













